Extracted text: Resolution No. 17: Encouraging VA to Conduct Research on the Effects of Anti-Malarial Drug Mefloquine for a Suspected Link to Mental Health Disabilities `
Extracted text: Resolution No. 17: Encouraging VA to Conduct Research on the Effects of Anti-Malarial Drug Mefloquine for a Suspected Link to Mental Health Disabilities ` results
admin
Edited Text
NATIONAL EXECUTIVE COMMITTEE
OF
THE AMERICAN LEGION
Indianapolis, Indiana
October 17-18, 2018
Resolution No. 17: Encouraging the Department of Veterans Affairs To Conduct Research
On The Effects Of Anti-Malarial Drug Mefloquine For A Suspected Link To Mental
Health Disabilities
Origin: Resolution No. 97 (WA) 2018 National Convention
Submitted By: Veterans Affairs & Rehabilitation Commission
WHEREAS, Mefloquine is an anti-malarial drug that has been commonly used in military
settings since its development by the U.S. military in the late 1980s; and
WHEREAS, The anti-malarial drug Mefloquine (commonly marketed as Lariam) had until
recently enjoyed a long history of preferred use in certain military settings in the prophylaxis of
chloroquine-resistant Plasmodium falciparum malaria; and
WHEREAS, Originally developed by the U.S. military in a Vietnam War-era drug
development program and subsequently licensed for prophylactic use in the U.S. in 1989; and
WHEREAS, Mefloquine has, in the over quarter century since, been widely used by the
U.S. military and by various international militaries during deployments in malaria-endemic areas,
including the Horn of Africa, sub-Saharan Africa, Australia, Southeast Asia and the Middle East,
particularly during recent large-scale operation in Iraq and Afghanistan; and
WHEREAS, Recently, Mefloquine was recognized as an idiosyncratic neurotoxicity that
may cause permanent injury to the central nervous system; and
WHEREAS, Very common side effects including insomnia and abnormal dreaming
affecting greater than 10% of the prescription users and common side effects including anxiety
and depression; and
WHEREAS, Other side effects described as uncommon but reported in between one and
ten prescribed users per 1000 including agitation, aggression, restlessness, panic attacks, mood
swings and confusion; and
WHEREAS, Among susceptible individuals, such symptoms may progress to a potentially
life-threatening condition; and
WHEREAS, With recent understanding of the adverse neurological effects of Mefloquine
on structures in the brainstem, research had emerged demonstrating that Mefloquine may impair
motor learning during certain complex tasks, such as those comparable to marksmanship, with
clinical implications for Mefloquine users; and
WHEREAS, Although not unique to military settings, concern of suicide associated with
use of the drug has also been a pervasive concern, particularly in the U.S. military, dating at least
back to the first large-scale deployment of troops to Iraq in 2003 during which use of Mefloquine
was widespread; now, therefore, be it
RESOLVED, By the National Executive Committee of The American Legion in
regular meeting assembled in Indianapolis, Indiana, on October 17-18, 2018, That The
American Legion encourage the Department of Veterans Affairs to conduct research on the
effects of Mefloquine as a reviewable condition for mental health disabilities.
OF
THE AMERICAN LEGION
Indianapolis, Indiana
October 17-18, 2018
Resolution No. 17: Encouraging the Department of Veterans Affairs To Conduct Research
On The Effects Of Anti-Malarial Drug Mefloquine For A Suspected Link To Mental
Health Disabilities
Origin: Resolution No. 97 (WA) 2018 National Convention
Submitted By: Veterans Affairs & Rehabilitation Commission
WHEREAS, Mefloquine is an anti-malarial drug that has been commonly used in military
settings since its development by the U.S. military in the late 1980s; and
WHEREAS, The anti-malarial drug Mefloquine (commonly marketed as Lariam) had until
recently enjoyed a long history of preferred use in certain military settings in the prophylaxis of
chloroquine-resistant Plasmodium falciparum malaria; and
WHEREAS, Originally developed by the U.S. military in a Vietnam War-era drug
development program and subsequently licensed for prophylactic use in the U.S. in 1989; and
WHEREAS, Mefloquine has, in the over quarter century since, been widely used by the
U.S. military and by various international militaries during deployments in malaria-endemic areas,
including the Horn of Africa, sub-Saharan Africa, Australia, Southeast Asia and the Middle East,
particularly during recent large-scale operation in Iraq and Afghanistan; and
WHEREAS, Recently, Mefloquine was recognized as an idiosyncratic neurotoxicity that
may cause permanent injury to the central nervous system; and
WHEREAS, Very common side effects including insomnia and abnormal dreaming
affecting greater than 10% of the prescription users and common side effects including anxiety
and depression; and
WHEREAS, Other side effects described as uncommon but reported in between one and
ten prescribed users per 1000 including agitation, aggression, restlessness, panic attacks, mood
swings and confusion; and
WHEREAS, Among susceptible individuals, such symptoms may progress to a potentially
life-threatening condition; and
WHEREAS, With recent understanding of the adverse neurological effects of Mefloquine
on structures in the brainstem, research had emerged demonstrating that Mefloquine may impair
motor learning during certain complex tasks, such as those comparable to marksmanship, with
clinical implications for Mefloquine users; and
WHEREAS, Although not unique to military settings, concern of suicide associated with
use of the drug has also been a pervasive concern, particularly in the U.S. military, dating at least
back to the first large-scale deployment of troops to Iraq in 2003 during which use of Mefloquine
was widespread; now, therefore, be it
RESOLVED, By the National Executive Committee of The American Legion in
regular meeting assembled in Indianapolis, Indiana, on October 17-18, 2018, That The
American Legion encourage the Department of Veterans Affairs to conduct research on the
effects of Mefloquine as a reviewable condition for mental health disabilities.